Difference between revisions of "Alopecia - Hair Loss"
From DolceraWiki
(→Inhibition of 5- - reductase by Finasteride) |
(→Structure-Activity Relationships(SARs)) |
||
| (326 intermediate revisions by 32 users not shown) | |||
| Line 1: | Line 1: | ||
| + | {{TOCrightEx}} | ||
== Rationale == | == Rationale == | ||
| − | * | + | * "Medication for men plagued by hair loss has become a topic of interest in Japan since a drug company began marketing it at the end of last year." March 5th, 2006 – [http://stophair.setupmyblog.com/?p=55 Source] |
| + | * "An increasing number of companies are apparently turning the Chinese fear of a bald spot into big bucks with some doing so well they are branching out into other countries." February 16, 2006 – [http://stophair.setupmyblog.com/ Source] | ||
| + | * "There is something in the air, or should we say in the hair, these days. Scientific research into hair loss remedies has never been more active or more exciting." June 7, 2006 - [http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/06-07-2005/0003821470&EDATE= Source]<br><br> | ||
| + | <br> | ||
| − | + | == Introduction == | |
| − | == | + | === Hair basics === |
| − | [http://www. | + | * Hair is a complex and delicate part of the body. |
| + | * Keeping it healthy and beautiful is a challenge. | ||
| + | * Hair grows everywhere on the body with the exception of lips, eyelids, palms of the hands and soles of the feet. | ||
| + | * Hair is basically a form of skin. | ||
| + | * Hair is made up of a protein called keratin. | ||
| + | * Each shaft of hair is made of two or three inter-twined layers of keratin which grow from a follicle beneath the skin. | ||
| + | * Hair Structure - [http://www.pg.com/science/haircare/hair_twh_12.htm Source] | ||
| + | * Hair Cycle - [http://www.follicle.com/hair-structure-life-cycle.html Source] | ||
| − | + | [[Image:Hairbasics.jpg|center|400px|Structure of Hair root and Hair bulb]] | |
| − | === | + | === What causes hair loss? === |
| − | * | + | * Decrease in growth of hair |
| − | * | + | * Increase in shedding of hair |
| − | * | + | * Breakage of hair |
| − | * | + | * Conversion of thick terminal hairs to thin vellus hairs |
| − | [[Image: | + | [[Image:Facts.jpg|thumb|right|250px|Survey results from Japan]] |
| + | Both men and women lose hair for similar reasons. Hair loss in men is often more dramatic, and follows a specific pattern of loss, one of which has been termed “Male Pattern Baldness" or "Androgenetic Alopecia". | ||
| − | |||
| − | |||
| − | |||
| − | '''Main | + | === Types of alopecia=== |
| + | |||
| + | * Alopecia Areata (AA): Hair loss occurring in patches anywhere on the body. | ||
| + | * Alopecia Totalis (AT): Total loss of the hair on the scalp. | ||
| + | * Alopecia Universalis (AU): Total loss of all hair on the body. | ||
| + | * Alopecia Barbae: Loss of facial hair (for a man) especially in the beard area. | ||
| + | * Alopecia Mucinosa: A type of alopecia which results in scaley patches. | ||
| + | * Androgenetic Alopecia (AGA): Also known as male pattern baldness. It is a thinning of the hair to an almost transparent state, in both men or women. It is thought to be a hereditary form of hair loss. | ||
| + | * Traction Alopecia: Traction alopecia is usually due to excessive pulling or tension on hair shafts as a result of certain hair styles. It is seen more often in women, particularly those of East Indian and Afro-Caribbean origin. Hair loss depends on the way the hair is being pulled. Prolonged traction alopecia can stop new hair follicles from developing and leads to permanent hair loss. | ||
| + | * Anagen Effluvium: This hair loss is generally caused by chemicals such as those used to treat cancer. Initially it causes patchy hair loss, which often then leads to total hair loss. The good news is that when you stop using these chemicals the hair normally grows back (usually about 6 months later). Other drugs also can cause hair loss. Many medicines used to treat even common diseases can cause hair loss. | ||
| + | * Scarring Alopecia: A form of alopecia which leaves scarring on the area of hair loss. | ||
| + | * Telogen Effluvium: A form of hair loss where more than normal numbers of hair fall out. There is a general 'thinning' of the hair. Unlike some other hair and scalp conditions, it is temporary and the hair growth usually recovers. ([http://www.alopeciaonline.org.uk/about/types.asp Source]) | ||
| + | |||
| + | === Androgenetic alopecia === | ||
| + | * Gradual onset | ||
| + | * Transition from large, thick, pigmented terminal hairs to thinner, shorter, indeterminate hairs and finally to short, wispy, non-pigmented vellus hairs in the involved areas | ||
| + | * Characterized by a receding hairline and/or hair loss on the top of the head | ||
| + | |||
| + | '''Main causes''' | ||
| + | * Genetic predisposition | ||
* Hormonal effect of androgen | * Hormonal effect of androgen | ||
* Reduction of blood circulation around hair follicle | * Reduction of blood circulation around hair follicle | ||
| Line 32: | Line 60: | ||
(JICST-EPlus - Japanese Science & Technology) | (JICST-EPlus - Japanese Science & Technology) | ||
| − | == | + | == IP activity over the years == |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
The graph indicates: | The graph indicates: | ||
* Number of patents filed every 5 years (except for first 7 years). | * Number of patents filed every 5 years (except for first 7 years). | ||
| Line 67: | Line 67: | ||
[[Image:Year1.jpg|thumb|center|400px|IP Activity over years]] | [[Image:Year1.jpg|thumb|center|400px|IP Activity over years]] | ||
| − | == Major | + | == Major players == |
| − | [[Image:players.jpg|thumb|left| | + | [[Image:players.jpg|thumb|left|500px|Assignees with more than 20 patents ]] |
| − | [[Image:players1.jpg|thumb|center| | + | [[Image:players1.jpg|thumb|center|500px|Assignees with fewer than 20 patents ]]<br> |
| − | * '''Active | + | * '''Active assignees''' |
Assignees currently active with more than 5 patents to their credit during 2000-2005. | Assignees currently active with more than 5 patents to their credit during 2000-2005. | ||
* Warner with 9 patents, | * Warner with 9 patents, | ||
| Line 79: | Line 79: | ||
[[Image:Active.jpg|thumb|center|500px|Active Assignees]] | [[Image:Active.jpg|thumb|center|500px|Active Assignees]] | ||
| − | == Anti-androgens | + | == Taxonomy == |
| − | * Anti-androgen | + | |
| − | * | + | [[Image:Alopecia toxonomy.jpg|thumb|center|800px]] |
| − | * DHT attaches to | + | |
| − | * DHT causes | + | == Interactive Taxonomy == |
| + | ''Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy'' <br> | ||
| + | ''Click on the red arrow on the side of a node name to view the content for that particular node in the dashboard'' | ||
| + | |||
| + | <mm>[[Map12.mm]]</mm> | ||
| + | |||
| + | == Treatment Approaches== | ||
| + | Composition of treatment for causes are identified and categorized as follows: | ||
| + | |||
| + | * Anti-androgens (Finasteride) [http://www.emedicine.com/DERM/topic21.htm source] | ||
| + | * Vasodilators (Minoxidil) [http://www.emedicine.com/DERM/topic21.htm source] | ||
| + | * Double action (Anti-androgen + Vasodilator) | ||
| + | * Hair matrix cells activator | ||
| + | |||
| + | {|border="1" cellpadding="2", style="#008080" align="center" | ||
| + | |- style="font-weight:bold" valign="top" | ||
| + | ! Cause !! Treatment approach !! Pathways affected | ||
| + | |||
| + | |- valign="top" | ||
| + | | Hormonal effect of androgen || Anti-androgens || Testosterone pathway | ||
| + | |||
| + | |- valign="top" | ||
| + | | Reduction of blood circulation around hair follicle || Vasodilators (eg. Minoxidil) || NO/cGMP Pathway | ||
| + | |||
| + | |- valign="top" | ||
| + | | Deactivation of hair matrix cells || Hair matrix cells activator | ||
| + | | | ||
| + | * Wnt pathway | ||
| + | * STAT pathway | ||
| + | * TGF beta/BMP Pathway | ||
| + | * FGF Pathway | ||
| + | * MAPK Pathway | ||
| + | * NOTCH Pathway | ||
| + | * Hedgehog Pathway | ||
| + | |} | ||
| + | |||
| + | === Anti-androgens === | ||
| + | * Anti-androgens are used in hormone therapy. | ||
| + | * Anti-androgens are designed to affect the hormones made in the adrenal glands. They don't stop the hormones from being made, but they stop them from having an effect leading to hair loss. | ||
| + | |||
| + | '''What causes hair loss?''' | ||
| + | * Testosterone is reduced to its active metabolite, Dihydrotestosterone (DHT) by the enzyme 5 alpha reductase. | ||
| + | * DHT attaches to androgen receptor sites at the hair follicle. | ||
| + | * DHT causes gradual miniaturization of the follicle, which eventually results in hair loss. | ||
| + | |||
| + | '''How do anti-androgens treat hair loss?''' | ||
| + | * Anti-androgens compete with DHT to bind to the androgen receptor. | ||
| + | * Upon binding of anti-androgen in place of DHT, follicle miniaturization is lowered and hair loss prevented. | ||
| − | === Functions of Anti-androgen === [http://www.revivogen.com/revivogen/work.html Anti-androgen] | + | ==== Functions of Anti-androgen ==== |
| + | [http://www.revivogen.com/revivogen/work.html Anti-androgen] | ||
[[Image:Andogen1.jpg|thumb|center|500px|Functions of Anti-androgen]] | [[Image:Andogen1.jpg|thumb|center|500px|Functions of Anti-androgen]] | ||
| − | === IP Map for | + | ==== IP Map for anti-androgen ==== |
| − | {| border="1" cellpadding=" | + | {| border="1" cellpadding="0", style="#008080" |
| − | !width=" | + | !width="120" bgcolor=DodgerBlue|'''Pat/Pub#''' |
| − | !width=" | + | !width="100" bgcolor=DodgerBlue|'''Nature''' |
| − | !width=" | + | !width="450" bgcolor=DodgerBlue|'''Composition''' |
| − | !width=" | + | !width="400" bgcolor=DodgerBlue|'''Composition action''' |
|- style="height:20px" | |- style="height:20px" | ||
| − | |bgcolor=LightCyan|[ | + | |bgcolor=LightCyan|[[US20060009430]] |
BLOTECH (2004) | BLOTECH (2004) | ||
|bgcolor=LightCyan|Natural extracts | |bgcolor=LightCyan|Natural extracts | ||
| Line 112: | Line 160: | ||
|bgcolor=LightCyan|Organic compound | |bgcolor=LightCyan|Organic compound | ||
|bgcolor=LightCyan|New class of 4-cycloalkoxy benzonitrile derivatives and salts | |bgcolor=LightCyan|New class of 4-cycloalkoxy benzonitrile derivatives and salts | ||
| − | |bgcolor=LightCyan|Acts as androgen receptor | + | |bgcolor=LightCyan|Acts as androgen receptor modulator and blocks formation of DHT. |
|- style="height:20px" | |- style="height:20px" | ||
|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050085467%22.PGNR.&OS=DN/20050085467&RS=DN/20050085467 US20050085467] | |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220050085467%22.PGNR.&OS=DN/20050085467&RS=DN/20050085467 US20050085467] | ||
| Line 142: | Line 190: | ||
|bgcolor=LightCyan|Peptides/nucleic acid | |bgcolor=LightCyan|Peptides/nucleic acid | ||
|bgcolor=LightCyan|Bradykinin antagonist (peptide of plasma origin from kininogen precursor-kallikrein) | |bgcolor=LightCyan|Bradykinin antagonist (peptide of plasma origin from kininogen precursor-kallikrein) | ||
| − | |bgcolor=LightCyan| | + | |bgcolor=LightCyan|Inhibits synthesis of bradykinin receptors or compounds by binding to B2 receptor |
|- style="height:20px" | |- style="height:20px" | ||
|bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0279010&F=0 EP0279010] | |bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=EP0279010&F=0 EP0279010] | ||
| Line 151: | Line 199: | ||
|} | |} | ||
| − | == Minoxidil == | + | === Minoxidil (Vasodilators) === |
| − | * A thick network of tiny veins and arteries | + | * Minoxidil is a "potassium channel opener" that leads to vasodilation. |
| − | * | + | * The drug is available in two forms. Oral minoxidil is used to treat high blood pressure and the topical solution form is used to treat hair loss and baldness. |
| + | |||
| + | '''What causes hair loss?''' | ||
| + | * A thick network of tiny veins and arteries line the outer wall of the follicle. Blood pumps through the bulb and hair via this network. | ||
| + | * DHT accumulates in the hair follicles and roots, constricting the blood supply of oxygen and nutrients to the hair roots; which is also seen to possibly contribute towards hair loss. | ||
| + | |||
| + | '''How does Minoxidil treat hair loss?''' | ||
| + | * Minoxidil is applied to the scalp topically, where it dilates blood vessels in the scalp and sustains the hair follicles for longer period of time. | ||
| + | * Minoxidil is thought to have a direct mitogenic effect on epidermal cells, as has been observed both in vitro and in vivo. Though the mechanism of its action for causing cell proliferation is not very clear, minoxidil is thought to prevent intracellular calcium entry. Calcium normally enhances epidermal growth factors to inhibit hair growth, and Minoxidil by getting converted to minoxidil sulfate acts as a potassium channel agonist and enhances potassium ion permeability to prevent calcium ions from entering into cells. ([http://www.hairtransplantadvice.com/medical-hair-restoration.php Source]) | ||
* Minoxidil sulfate (MS) appears to be the active metabolite responsible for hair growth stimulation. | * Minoxidil sulfate (MS) appears to be the active metabolite responsible for hair growth stimulation. | ||
| − | === Functions of | + | ==== Functions of Vasodilators ==== |
| − | [[Image:minoxidil1.jpg|thumb|center|500px|Functions of Monoxidil]] | + | [[Image:minoxidil1.jpg|thumb|center|500px|Functions of Monoxidil [http://www.nurseminerva.co.uk/diagrams.htm#Diagram%201 source]]] |
| − | === IP Map for | + | ==== IP Map for Vasodilators ==== |
{| border="1" cellpadding="2" | {| border="1" cellpadding="2" | ||
| − | !width=" | + | !width="120" bgcolor=DodgerBlue|'''Pat/Pub#''' |
!width="75" bgcolor=DodgerBlue|'''Nature''' | !width="75" bgcolor=DodgerBlue|'''Nature''' | ||
| − | !width=" | + | !width="600" bgcolor=DodgerBlue|'''Composition''' |
!width="300" bgcolor=DodgerBlue|'''Composition action''' | !width="300" bgcolor=DodgerBlue|'''Composition action''' | ||
|- style="height:100px" | |- style="height:100px" | ||
| Line 181: | Line 237: | ||
|} | |} | ||
| − | == Double action (Anti-androgen + | + | === Double action (Anti-androgen + Vasodilator) === |
| − | * Combination of | + | * Combination of Vasodilator + Anti-androgen (double action) composition for effective treatment of Male-Pattern Baldness. |
| − | + | '''What is the problem with using only Anti-androgen therapy?''' | |
| − | + | * Anti-androgen is not effective in addressing the issue of vasocontriction around hair follicles due to sebum oil build up. | |
| + | * Anti-androgen only prevents binding of DHT to androgen receptors. However, the effects of improper oxygen and nutrient supply to the brain due to vasocontriction still remains and gradually causes hair loss. | ||
| − | === IP Map for (Anti-androgen + | + | '''What is the problem with using only Vasodilator (or Minoxidil only) therapy?''' |
| + | * Vasodilator or Minoxidil-based products are generally not effective in stopping hair loss as vasodilators (or Minoxidil) do not block the harmful effects of DHT in the scalp and hair follicles. | ||
| + | * Vasodilators or Minoxidil simply dilate blood vessels in the scalp. However, the harmful DHT still gets produced in the body, enters the scalp and hair follicles causing hair loss. | ||
| + | |||
| + | '''How is the combination of Anti-androgens and Vasodilator (or Minoxidil) effective?''' | ||
| + | * Anti-androgens target the problem of DHT binding to androgen receptors and prevents follicle miniaturization. | ||
| + | * Vasodilators like Minoxidil cause vasodilation and therefore improve supply of oxygen and nutrients to the hair follicle and roots. | ||
| + | * Combination therapy therefore proves to be much more effective than individual therapy. | ||
| + | |||
| + | ==== Functions of (Anti-androgen + Vasodilators) ==== | ||
| + | [http://www.revivogen.com/revivogen/work.html Anti-androgen ]and [http://www.xandrox.net/articles/article01.htm Minoxidil] | ||
| + | [[Image:Doubleaction1.jpg|thumb|center|500px|Functions of (Anti-androgen + Vasodilators)]] | ||
| + | |||
| + | ==== IP Map for (Anti-androgen + Vasodilators) ==== | ||
{| border="1" cellpadding="3" | {| border="1" cellpadding="3" | ||
| − | !width=" | + | !width="120" bgcolor=DodgerBlue|'''Pat/Pub#''' |
!width="75" bgcolor=DodgerBlue|'''Nature''' | !width="75" bgcolor=DodgerBlue|'''Nature''' | ||
| − | !width=" | + | !width="500" bgcolor=DodgerBlue|'''Composition''' |
| − | !width=" | + | !width="500" bgcolor=DodgerBlue|'''Composition action''' |
|- style="height:100px" | |- style="height:100px" | ||
|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060052405%22.PGNR.&OS=DN/20060052405&RS=DN/20060052405 US20060052405] | |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220060052405%22.PGNR.&OS=DN/20060052405&RS=DN/20060052405 US20060052405] | ||
N/A(2000) | N/A(2000) | ||
|bgcolor=LightCyan|Peptides | |bgcolor=LightCyan|Peptides | ||
| − | |bgcolor=LightCyan|Testosterone blocker or vascular toner (Flutamide, cyproterone acetate, spironolactone, progesterone, or analogs or derivatives) and minoxidil mixed along with non-retinoid penetration | + | |bgcolor=LightCyan|Testosterone blocker or vascular toner (Flutamide, cyproterone acetate, spironolactone, progesterone, or analogs or derivatives) and minoxidil mixed along with non-retinoid penetration enhancer and sunscreen |
|bgcolor=LightCyan|Inhibits 5.alpha.-reductase activity (block DHT) and increase blood flow on the scalp | |bgcolor=LightCyan|Inhibits 5.alpha.-reductase activity (block DHT) and increase blood flow on the scalp | ||
|- style="height:100px" | |- style="height:100px" | ||
| Line 213: | Line 283: | ||
|} | |} | ||
| + | === Hair matrix cell activator === | ||
| + | Hair matrix cell activator is a substance that acts at the matrix cells in the hair follicle preventing their degradation. | ||
| − | + | '''What causes hair loss?''' | |
| − | * Stem cells | + | * Stem cells are interspersed within the basal layer of the outer root sheath and in an area called the bulge. |
| − | * | + | * Stem cells migrate to hair matrix where they start to divide and differentiate, under the influence of substances produced by cells of the dermal papilla. |
| − | + | * Perifollicular matrix cells undergo slow degradation which prevents follicle stimulation. | |
| + | * Hair follicle activation is required for hair growth and thus inhibition of follicle activation eventually leads to hair loss. | ||
| − | === Functions of Hair matrix cell activator === [http://www.ijdb.ehu.es/fullaccess/fulltext.04023/ft163.pdf Hair matrix cell activator] | + | |
| + | '''How does hair cell matrix activator treat hair loss?''' | ||
| + | * Hair cell matrix activator slows down and inhibits degradation of the perifollicular matrix. | ||
| + | * This leads to an increase in hair follicle matrix cells that differentiate from progenitor stem cells. | ||
| + | * Matrix activator allows activation of hair matrix cells and therefore follicle stimulation leading to hair growth. | ||
| + | |||
| + | ==== Functions of Hair matrix cell activator ==== | ||
| + | [http://www.ijdb.ehu.es/fullaccess/fulltext.04023/ft163.pdf Hair matrix cell activator] | ||
[[Image:Hair matrix.jpg|thumb|center|500px|Functions of Hair matrix cell activator ]] | [[Image:Hair matrix.jpg|thumb|center|500px|Functions of Hair matrix cell activator ]] | ||
| − | === IP Map for Hair matrix cell activator === | + | ==== IP Map for Hair matrix cell activator ==== |
{| border="1" cellpadding="2" | {| border="1" cellpadding="2" | ||
| − | !width=" | + | !width="120" bgcolor=DodgerBlue|'''Pat/Pub#''' |
| − | !width=" | + | !width="100" bgcolor=DodgerBlue|'''Nature''' |
| − | !width=" | + | !width="200" bgcolor=DodgerBlue|'''Composition''' |
| − | !width=" | + | !width="600" bgcolor=DodgerBlue|'''Composition action''' |
| − | |- style="height: | + | |- style="height:50px" |
|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220020052498%22.PGNR.&OS=DN/20020052498&RS=DN/20020052498 US20020052498] | |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220020052498%22.PGNR.&OS=DN/20020052498&RS=DN/20020052498 US20020052498] | ||
SHISEIDO(1999) | SHISEIDO(1999) | ||
| Line 234: | Line 314: | ||
|bgcolor=LightCyan|(2-substituted oxyphenyl) alkanamide derivative and its salt | |bgcolor=LightCyan|(2-substituted oxyphenyl) alkanamide derivative and its salt | ||
|bgcolor=LightCyan|Mechanism of action has not been made clear, having excellent hair follicle activating action and regrowth promoting effect | |bgcolor=LightCyan|Mechanism of action has not been made clear, having excellent hair follicle activating action and regrowth promoting effect | ||
| − | |- style="height: | + | |- style="height:50px" |
|bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040071647%22.PGNR.&OS=DN/20040071647&RS=DN/20040071647 US20040071647] | |bgcolor=LightCyan|[http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220040071647%22.PGNR.&OS=DN/20040071647&RS=DN/20040071647 US20040071647] | ||
L'OREAL(1998) | L'OREAL(1998) | ||
|bgcolor=LightCyan|Peptides | |bgcolor=LightCyan|Peptides | ||
|bgcolor=LightCyan|Metalloprotease (MMP-9) inhibitor (thiol or a hydroxamate) other than chelating calcium ions | |bgcolor=LightCyan|Metalloprotease (MMP-9) inhibitor (thiol or a hydroxamate) other than chelating calcium ions | ||
| − | |bgcolor=LightCyan|Reducing the expression of MMPs (Metalloproteases) in the scalp - | + | |bgcolor=LightCyan|Reducing the expression of MMPs (Metalloproteases) in the scalp - slows down or inhibits the degradation of the perifollicular matrix (extracellular matrix surrounding the hair follicle) |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
|} | |} | ||
| − | == | + | == Technology mapping based on patents analyzed == |
| − | === | + | === IPMap: Composition nature matrix === |
{| border="1" cellpadding="11", style="#008080" | {| border="1" cellpadding="11", style="#008080" | ||
| − | !width=" | + | !width="120" bgcolor=DodgerBlue|'''Year''' |
| − | !width=" | + | !width="200" bgcolor=DodgerBlue|'''Organic Compound''' |
| − | !width=" | + | !width="200" bgcolor=DodgerBlue|'''Natural extracts''' |
| − | !width=" | + | !width="200" bgcolor=DodgerBlue|'''Peptides''' |
| − | !width=" | + | !width="200" bgcolor=DodgerBlue|'''Nucleotides''' |
| − | !width=" | + | !width="200" bgcolor=DodgerBlue|'''Natural extract + Organic comp''' |
|- style="height:10px" | |- style="height:10px" | ||
|bgcolor=LightCyan|2005 | |bgcolor=LightCyan|2005 | ||
| Line 307: | Line 352: | ||
|bgcolor=LightCyan|APHIOS (1) | |bgcolor=LightCyan|APHIOS (1) | ||
|bgcolor=LightCyan|.... | |bgcolor=LightCyan|.... | ||
| − | |bgcolor=LightCyan| | + | |bgcolor=LightCyan|FUNDACION (1) |
|bgcolor=LightCyan|.... | |bgcolor=LightCyan|.... | ||
|- | |- | ||
| Line 366: | Line 411: | ||
|bgcolor=LightCyan|.... | |bgcolor=LightCyan|.... | ||
|} | |} | ||
| − | + | === Focus of patents === | |
| − | == Focus of patents == | + | |
{| border="1" cellpadding="17", style="#008080" | {| border="1" cellpadding="17", style="#008080" | ||
| − | !width=" | + | !width="800" bgcolor=DodgerBlue|'''Focus of patents''' |
| − | !width=" | + | !width="150" bgcolor=DodgerBlue|'''Patent no.''' |
| − | !width=" | + | !width="100" bgcolor=DodgerBlue|'''Rec. no.''' |
|- | |- | ||
|bgcolor=LightCyan|2-substituted oxyphenyl alkanamide derivative having excellent hair growth effect. | |bgcolor=LightCyan|2-substituted oxyphenyl alkanamide derivative having excellent hair growth effect. | ||
| Line 443: | Line 487: | ||
|} | |} | ||
| − | === | + | === Technology focus=== |
[[Image:Technologyfocus2.jpg|thumb|center|700px|Technology focus]] | [[Image:Technologyfocus2.jpg|thumb|center|700px|Technology focus]] | ||
| − | + | === Distribution of patents === | |
| − | == Distribution of patents == | + | |
| − | === | + | ==== By patent types ==== |
[[Image:Didtribution.jpg|thumb|center|700px|Distribution based on patent types ]] | [[Image:Didtribution.jpg|thumb|center|700px|Distribution based on patent types ]] | ||
| − | === | + | ==== By key ingredients ==== |
[[Image:key1.jpg|thumb|center|700px|Distribution of key ingredients]] | [[Image:key1.jpg|thumb|center|700px|Distribution of key ingredients]] | ||
| − | === | + | ==== By target disease ==== |
[[Image:target.jpg|thumb|center|700px|Distribution based on target diseases]] | [[Image:target.jpg|thumb|center|700px|Distribution based on target diseases]] | ||
| − | === Key ingredients vs. Target disease | + | ==== Key ingredients vs. Target disease ==== |
[[Image:key&target1.jpg|thumb|center|1000px|Key ingredients vs. Target disease]] | [[Image:key&target1.jpg|thumb|center|1000px|Key ingredients vs. Target disease]] | ||
| − | === Target species === | + | ==== Target species ==== |
[[Image:Species.jpg|thumb|center|700px|Target species]] | [[Image:Species.jpg|thumb|center|700px|Target species]] | ||
| − | === Mode of administration === | + | |
| + | ==== Mode of administration ==== | ||
[[Image:Mode.jpg|thumb|center|700px|Mode of administration]] | [[Image:Mode.jpg|thumb|center|700px|Mode of administration]] | ||
| − | === Product type vs. Product form === | + | ==== Product type vs. Product form ==== |
[[Image:prod.jpg|thumb|center|700px|Product type vs. Product form]] | [[Image:prod.jpg|thumb|center|700px|Product type vs. Product form]] | ||
| − | == | + | ==== Patents by target diseases ==== |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{| border="1" cellpadding="16", style="#008080" | {| border="1" cellpadding="16", style="#008080" | ||
| − | !width=" | + | !width="800" bgcolor=DodgerBlue|'''Target disease/ disorder''' |
| − | !width=" | + | !width="150" bgcolor=DodgerBlue|'''Patent no.''' |
| − | !width=" | + | !width="150" bgcolor=DodgerBlue|'''Rec. no.''' |
|- | |- | ||
|bgcolor=LightCyan|Alopecia areata, alopecia pityrodes or alopecia seborrheica, or androgenic alopecia (i.e. male pattern baldness) | |bgcolor=LightCyan|Alopecia areata, alopecia pityrodes or alopecia seborrheica, or androgenic alopecia (i.e. male pattern baldness) | ||
| Line 600: | Line 589: | ||
|} | |} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | == | + | ==== [[List of patents]] ==== |
| + | == Pathways and linkages == | ||
| + | |||
| + | === Pathways associated with hair matrix cell activation=== | ||
| + | |||
| + | '''Molecular mediators of hair follicle embryogenesis:''' Identification of the molecular pathways controlling differentiation and proliferation in mammalian hair follicles provides the crucial link to understanding the regulation of normal hair growth, the basis of hereditary hair loss diseases, and the origin of follicle-based tumors. Homeobox (hox), hedgehog (hh), patched (ptc), wingless (wg}/wnt, disheveled (dsh), engrailed (en), Notch 1 and armadillo/B-catenin genes are all critical for hair follicle. | ||
| + | |||
| + | * '''Wnt pathway:''' Maintains hair-inducing activity of the dermal papilla. | ||
| + | * '''Hedgehog pathway:''' Sonic hedgehog (SHH) signaling plays a critical role in hair follicle development. Sonic hedgehog gene. Sonic hedgehog, SHH for short, helps guide hair follicles from a resting stage into growth activity. SHH is particularly important in the embryonic formation of hair follicles. | ||
| + | * '''STAT pathway''' | ||
| + | * '''TGF beta/BMP Pathway:''' Bone morphogenetic protein (BMP) signaling have been implicated in the regulation of both proliferation and differentiation in the hair follicle. BMP2 is expressed in the embryonic ectoderm, but then localizes to the early hair follicle placode and underlying mesenchyme. BMP4 is expressed in the early dermal condensate. Research results show that BMPs are a key component of the signaling network controlling hair development and are required to induce the genetic program regulating hair shaft differentiation in the anagen hair follicle. Transforming growth factor beta (TGF-beta), inhibits mitogen - induced dermal papilla cell proliferation | ||
| + | * '''FGF Pathway:''' Fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) potentiate the growth of dermal papilla cells. It is proposed that these proteins increase the synthesis of stromelysin (an enzyme, matrix metalloproteinase) which acts on the papilla cells and accelerates their growth. | ||
| + | * '''MAPK Pathway:''' Mitogen-activated protein kinase (MAPK) activation, increases keratinocyte turnover. | ||
| + | * '''NOTCH Pathway''': Notch-1 is expressed in ectodermal-derived cells of the follicle, in the inner cells of the embryonic placode and the follicle bulb, and in the suprabasal cells of the mature outer root sheath. Delta-1, one of the three ligands is only expressed during embryonic follicle development and is exclusive to the mesenchymal cells of the pre-papilla located beneath the follicle placode, and appears to promote and accelerate placode formation, while suppressing placode formation in surrounding cells. Other ligands, Serrate 1 and Serrate 2, are expressed in matrix cells destined to form the inner root sheath and hair shaft. | ||
| + | |||
| + | === Pathways associated with Anti Androgen=== | ||
| + | [[Image:Slide3.gif|center|720 px|Alopecia pathways]] | ||
| + | |||
| + | ==== Players of WNT inhibition Pathway ==== | ||
| + | [[Image:wnt.jpg|thumb|right|200 px|Wnt inhibition]] | ||
{| border="1" cellpadding="15", style="#008080" | {| border="1" cellpadding="15", style="#008080" | ||
| − | !width=" | + | !width="150" bgcolor=DodgerBlue|'''Patent no.''' |
| − | !width=" | + | !width="200" bgcolor=DodgerBlue|'''Key compound''' |
| − | !width=" | + | !width="200" bgcolor=DodgerBlue|'''Players of inhibition''' |
|- style="height:10px" | |- style="height:10px" | ||
|bgcolor=lightyellow|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6664247.PN.&OS=PN/6664247&RS=PN/6664247 US6664247] | |bgcolor=lightyellow|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6664247.PN.&OS=PN/6664247&RS=PN/6664247 US6664247] | ||
| Line 650: | Line 654: | ||
|bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO03011287&F=0 WO2003011287] | |bgcolor=LightCyan|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO03011287&F=0 WO2003011287] | ||
|bgcolor=LightCyan|Pyrazolon derivatives | |bgcolor=LightCyan|Pyrazolon derivatives | ||
| − | |bgcolor=LightCyan|GSK3, | + | |bgcolor=LightCyan|GSK3, ß-catenin |
|- | |- | ||
|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6924141.PN.&OS=PN/6924141&RS=PN/6924141 US6924141] | |bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6924141.PN.&OS=PN/6924141&RS=PN/6924141 US6924141] | ||
|bgcolor=LightCyan|Lithium chloride, Wnt3/4/ 7 | |bgcolor=LightCyan|Lithium chloride, Wnt3/4/ 7 | ||
| − | |bgcolor=LightCyan| | + | |bgcolor=LightCyan|ß-catenin, GSK3, Wnt |
|- | |- | ||
|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6706685.PN.&OS=PN/6706685&RS=PN/6706685 US6706685] | |bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6706685.PN.&OS=PN/6706685&RS=PN/6706685 US6706685] | ||
|bgcolor=LightCyan|Peptide sequence | |bgcolor=LightCyan|Peptide sequence | ||
| − | |bgcolor=LightCyan| | + | |bgcolor=LightCyan|ß-catenin |
|- | |- | ||
|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6683048.PN.&OS=PN/6683048&RS=PN/6683048 US6683048] | |bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6683048.PN.&OS=PN/6683048&RS=PN/6683048 US6683048] | ||
|bgcolor=LightCyan|Peptide sequence | |bgcolor=LightCyan|Peptide sequence | ||
| − | |bgcolor=LightCyan| | + | |bgcolor=LightCyan|a-catenin, ß-catenin |
|- | |- | ||
|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6677116.PN.&OS=PN/6677116&RS=PN/6677116 US6677116] | |bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6677116.PN.&OS=PN/6677116&RS=PN/6677116 US6677116] | ||
|bgcolor=LightCyan|Peptide sequence LXXLL | |bgcolor=LightCyan|Peptide sequence LXXLL | ||
| − | |bgcolor=LightCyan| | + | |bgcolor=LightCyan|ß-catenin |
|- | |- | ||
|bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6303576.PN.&OS=PN/6303576&RS=PN/6303576 US6303576] | |bgcolor=LightCyan|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6303576.PN.&OS=PN/6303576&RS=PN/6303576 US6303576] | ||
|bgcolor=LightCyan|Peptide sequence LXXLL | |bgcolor=LightCyan|Peptide sequence LXXLL | ||
| − | |bgcolor=LightCyan| | + | |bgcolor=LightCyan|ß-catenin |
|} | |} | ||
| − | |||
| − | |||
| − | |||
| + | ==== Role of Pyrazole compounds in Wnt Pathway==== | ||
| + | '''Pyrazole''' | ||
* '''Pyrazole''' (C3H4N2) refers both to the class of simple aromatic ring organic compounds of the heterocyclic series characterized by a 5-membered ring structure composed of three carbon atoms and two nitrogen atoms in adjacent positions and to the unsubstituted parent compound. Being so composed and having pharmacological effects on humans, they are classified as alkaloids although they are not known to occur in nature. | * '''Pyrazole''' (C3H4N2) refers both to the class of simple aromatic ring organic compounds of the heterocyclic series characterized by a 5-membered ring structure composed of three carbon atoms and two nitrogen atoms in adjacent positions and to the unsubstituted parent compound. Being so composed and having pharmacological effects on humans, they are classified as alkaloids although they are not known to occur in nature. | ||
| − | * Pyrazoles are produced synthetically through the reaction of | + | * Pyrazoles are produced synthetically through the reaction of a,ß-unsaturated aldehydes with hydrazine and subsequent dehydrogenation |
[[Image:pyrazole1.jpg|thumb|center|500px|Pyrazole (C3H4N2)]] | [[Image:pyrazole1.jpg|thumb|center|500px|Pyrazole (C3H4N2)]] | ||
* Pyrazoles are used for their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, tranquilizing, muscle relaxing, psychoanaleptic, anticonvulsant, monoamineoxidase inhibiting, antidiabetic and antibacterial activities. | * Pyrazoles are used for their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, tranquilizing, muscle relaxing, psychoanaleptic, anticonvulsant, monoamineoxidase inhibiting, antidiabetic and antibacterial activities. | ||
| Line 683: | Line 686: | ||
[[Image:pyrazole2.jpg|thumb|center|500px|Structurally related compounds]] | [[Image:pyrazole2.jpg|thumb|center|500px|Structurally related compounds]] | ||
| − | === GSK3 inhibition by pyrazole compounds === | + | ==== GSK3 inhibition by pyrazole compounds ==== |
[[Image:bold3.jpg]] | [[Image:bold3.jpg]] | ||
{| border="1" cellpadding="2", style="#008080" | {| border="1" cellpadding="2", style="#008080" | ||
| − | !width=" | + | !width="350"|[http://patft1.uspto.gov/netacgi/nph-Parser?TERM1=6989385+&Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=0&f=S&l=50 US6989385] |
[[Image:US6989385.jpg]] | [[Image:US6989385.jpg]] | ||
| − | !width=" | + | !width="350"|[http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6664247.PN.&OS=PN/6664247&RS=PN/6664247 US6664247] |
[[Image:US6664247.jpg]] | [[Image:US6664247.jpg]] | ||
| − | !width=" | + | !width="350"|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2005012256&F=0 WO2005012256] |
[[Image:WO2005012256.jpg]] | [[Image:WO2005012256.jpg]] | ||
|- | |- | ||
| Line 717: | Line 720: | ||
|} | |} | ||
| − | === | + | ==== Inhibition by amine derivatives ==== |
'''Patent Number''': US6989385 | '''Patent Number''': US6989385 | ||
'''Applicant''': ''Vertex Pharmaceuticals Incorporated'' | '''Applicant''': ''Vertex Pharmaceuticals Incorporated'' | ||
'''Title''': Pyrazole compounds useful as protein kinase inhibitors | '''Title''': Pyrazole compounds useful as protein kinase inhibitors | ||
| + | |||
'''Basic Structure''': | '''Basic Structure''': | ||
[[Image:pyrazol1.jpeg]] | [[Image:pyrazol1.jpeg]] | ||
| − | + | [[Derivatives of pyrimidine-pyrazole amine disclosed in US6989385 patent]] | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
'''Patent Number''': US7008948 | '''Patent Number''': US7008948 | ||
'''Applicant''': Vertex Pharmaceuticals Incorporated | '''Applicant''': Vertex Pharmaceuticals Incorporated | ||
'''Title''': Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors | '''Title''': Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors | ||
| + | |||
'''Basic Structure''' | '''Basic Structure''' | ||
[[Image:pyrazol2.jpeg]] | [[Image:pyrazol2.jpeg]] | ||
| − | + | [[Derivatives of pyrimidine-pyrazole amine disclosed in US7008948 patent]] | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
'''Patent Number''': US6977262 | '''Patent Number''': US6977262 | ||
'''Assignee''': Mitsubishi Pharma Corporation | '''Assignee''': Mitsubishi Pharma Corporation | ||
'''Title''': Dihydropyrazolopyridine compounds and pharmaceutical use thereof | '''Title''': Dihydropyrazolopyridine compounds and pharmaceutical use thereof | ||
| + | |||
'''Basic Structure''': | '''Basic Structure''': | ||
[[Image:pyrazol3.jpeg]] | [[Image:pyrazol3.jpeg]] | ||
| − | + | [[Derivatives of pyrimidine-pyrazole amine disclosed in US6977262 patent]] | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
---- | ---- | ||
'''Patent Number''': US6664247 | '''Patent Number''': US6664247 | ||
'''Assignee''': Vertex Pharmaceuticals Incorporated | '''Assignee''': Vertex Pharmaceuticals Incorporated | ||
'''Title''': Pyrazole compounds useful as protein kinase inhibitors''' | '''Title''': Pyrazole compounds useful as protein kinase inhibitors''' | ||
| + | |||
'''Basic Structure''': | '''Basic Structure''': | ||
[[Image:pyrazol4.jpeg]] | [[Image:pyrazol4.jpeg]] | ||
| − | + | [[Derivatives of pyrimidine-pyrazole amine disclosed in US6664247 patent]] | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
---- | ---- | ||
'''Patent Number''': US2004224944 | '''Patent Number''': US2004224944 | ||
'''Assignee''': VERTEX PHARMACEUTICALS INC | '''Assignee''': VERTEX PHARMACEUTICALS INC | ||
'''Title''': Pyrazole compounds useful as protein kinase inhibitors | '''Title''': Pyrazole compounds useful as protein kinase inhibitors | ||
| + | |||
'''Basic Structure''': | '''Basic Structure''': | ||
[[Image:pyrazol5.jpeg]] | [[Image:pyrazol5.jpeg]] | ||
| − | + | [[Derivatives of pyrimidine-pyrazole amine disclosed in US2004224944 patent]] | |
| − | + | [[Other derivates for alopecia]] | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | == Inhibition | + | ==== GSK-3 Inhibition Mechanism - Phosphorylation==== |
| − | [ | + | * ''GSK-3 inhibition targets treatment of chemotherapy-induced alopecia'' [http://www.biomedcentral.com/1471-2199/5/15 source] |
| + | * In the canonical Wnt signaling cascade, adenomatous polyposis coli (APC), axin, and GSK3 constitute the so-called destruction complex, which controls the stability of beta-catenin. It is generally believed that four conserved Ser/Thr residues in the N terminus of beta-catenin are the pivotal targets for the constitutively active serine kinase GSK3. GSK3 covalently modifies beta-catenin by attaching phosphate groups (from ATP) to serine, and threonine residues. In so doing, the functional properties of the protein kinase’s substrate (beta-catenin) are modified. | ||
| − | + | * In the absence of Wnt signals, glycogen synthase kinase (GSK) is presumed to phosphorylate the N-terminal end of beta-catenin, thus promote degradation of beta-catenin and subsequent ubiquitination and proteasomal targeting. | |
| − | + | ||
| − | + | * Exposure of cells to Wnts leads to inactivation of GSK-3 through an as yet unclear mechanism.The phosphoprotein Dishevelled is required, after receptor-ligand interaction, to transduce the signal that results in the inactivation of GSK-3. As a result, beta-catenin is dephosphorylated and escapes the ubiqduitylation-dependent destruction machinery. | |
| − | + | * Unphosphorylated beta-catanin accumulates in the cytoplasm and translocates to the nucleus, where it can associate with the TCF/LEFs and become a transcriptional transactivator. | |
| − | * | + | |
| − | + | ||
| − | + | ||
| − | ''' | + | '''[[More details on GSK-3]]''' |
| − | + | ||
| − | + | ||
| − | + | ||
| − | ''' | + | '''Key points''' |
| − | + | ||
| − | + | ||
| − | + | * Beta-catenin phosphorylation at serine 45 (Ser45), threonine 41 (Thr41), Ser37, and Ser33 is critical for beta-catenin degradation. [http://jb.oxfordjournals.org/cgi/content/abstract/132/5/697 source] | |
| − | * | + | * Regulation of beta-catenin phosphorylation is a central part of the canonical Wnt signaling pathway. [http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ProduktNr=223838&ArtikelNr=66755&filename=66755.pdf source] |
| + | * Ser-X-X-X-Ser (X is any amino acid) motif is obligatory for beta-catenin phosphorylation by GSK3.[http://lib.bioinfo.pl/auth:He,X source] | ||
| + | * Beta-catenin phosphorylation/degradation and its regulation by Wnt can occur normally in the absence of Thr41 as long as the Ser-X-X-X-Ser motif/spacing is preserved. [httSp://pubs.acs.org/cgi-bin/abstract.cgi/bichaw/2006/45/i16/abs/bi0601149.html source] | ||
| − | ''' | + | '''GK3 Inhibition:''' |
| − | + | ||
| − | + | ||
| − | + | * GSK3 is regulated by phosphorylation. | |
| + | * Phosphorylation of GSK3beta on Ser9 (Ser21 in GSK3alpha) by protein kinase B (PKB) causes its inactivation is the primary mechanism responsible for growth factor inhibition of this kinase. Activation of GSK3beta is dependent upon the phosphorylation of Tyr216 (Tyr279 in GSK3alpha). Upon activation, it has been shown to phosphorylate a number of different cellular proteins, including p53, c-Myc, c-Jun, heat shock factor-1 (HSF-1), beta-catenin and cyclin D1. [http://www.bioreagents.com/index.cfm/fuseaction/products.detail/CatNbr/OPA1-03082 source] | ||
| + | * GSK3 is inhibited by phosphorylation of serine-9 or serine-21 in GSK3beta and GSK3alpha, respectively. [http://lib.bioinfo.pl/auth:Friedman,AB source] | ||
| + | * GSK3’s substrate specificity is unique in that phosphorylation of substrate only occurs if a phosphoserine or phosphotyrosine is present four residues C-terminal to the site of GSK phosphorylation. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11430833&dopt=Abstract source] | ||
| + | * A phosphorylation cascade starts from GSK3 itself and initiates it in beta-catenin. [http://www.genesdev.org/cgi/content/full/16/16/2073 source] | ||
| + | * Thus our goal is to stop the phosphorylation of the serine and threonine residue of GSK3. | ||
| + | * The figure below illustrates the phosphorylation mechanism of serine and threonine by ATP. | ||
| − | + | [[image:GSK3_phosphorylation.jpg|400 px|center|thumb|Phosphorylation mechanism [http://images.google.com/images?q=tbn:DGnhgZ7y7pSejM:bass.bio.uci.edu/~hudel/bs99a/lecture26/phosphoaa.gif source]]] | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | |||
| − | |||
| + | * We can't stop conversion of ADP to ATP that relaseas Phosphorous group causing Phosphorylation. | ||
| + | * We can only block the oxygen atom on serine and threonine as a result which will in turn stop Phosphorylation. | ||
| + | * The two probable ways of blocking the oxygen atom are (a) As oxygen is a Lewis acid with strong electron donating capacity, so usually a strong electron pair acceptor can easily bind to oxygen atom and preventing phosphorylation or (b) breaking of the -OH bond with the carbon atom. | ||
| − | + | '''Serine - pyrazole reaction''' | |
| − | + | [[image:serine-pyrazol.jpg|600 px|center|thumb|Serine and Pyrazole reaction [http://www.genome.ad.jp/dbget-bin/www_bget?rn+R03134 source]]] | |
| − | + | ||
| − | + | ||
| − | + | * The T-loop of GSK-3 is tyrosine phosphorylated at Y216 and Y279 in GSK-3b and GSK-3a, respectively, but not threonine phosphorylated. Y216/Y279 phosphorylation could play a role in forcing open the substrate (e.g, beta-catanin)-binding site. | |
| − | + | * Thus, T-loop tyrosine might facilitate substrate phosphorylation but is not strictly required for kinase activity. | |
| − | + | * Stimulation of cells with pyrazole compounds cause inactivation of GSK-3 through phosphorylation (S9 of GSK-3 beta and S21 of GSK-3 alpha), which inhibits GSK-3 activity. Thus leading to dephosphorylation of substrates (e.g., beta-catanin) resulting in their functional activation and consequent increased hair follicle morphogenisis. | |
| − | * | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | === | + | * Phosphorylation of S9/S21 creates a primed pesudosubstrate that binds intramolecularly to the positively charged pocket of the GSK-3. This folding precludes phosphorylation of substrates (eg., beta-catanin) because the catalytic groove is occupied. The mechanism of inhibition is competitive. |
| − | + | ||
| − | + | * A consequence of this is that primed substrates, in high enough concentrations, out-compete the pesudosubstrate and thus become phosphorylated. | |
| − | + | ||
| − | + | * Thus, small molecule inhibitors modeled to fit in the positively charged pocket of the GSK-3 kinease domain could potentially be very effective for selective inhibition of primed substrates. | |
| + | |||
| + | '''Proposed mechanisms to regulate GSK-3''' [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12615961 source] | ||
| + | |||
| + | # inactivation of GSK-3 through serine phosphorylation | ||
| + | # activation of GSK-3 through tyrosine phosphorylation | ||
| + | # inactivation of GSK-3 through tyrosine dephosphorylation | ||
| + | # Covalant modifications of substrates through priming phosphorylation | ||
| + | # inhibition or facilation of GSK-3 mediated substrate phosphorylation thriugh interation of GSK-3 with binding or scaffolding proteins | ||
| + | # targeting of GSK-3 to different subcellular localizations | ||
| + | # differential usage of isoforms or splice variants to alter subcellular localization or substrate specificity | ||
| + | # integration of parellel signals conveyed by a signal stimulus. | ||
| + | |||
| + | '''Key Finding''' | ||
| + | * '''Pyrazole compounds with inhibition constant (Ki) of <0.1 mM''' are a good starting point for developing molecules that can inhibit serine/threonine protein kinase (such as GSK-3) and the proteins they help to regulate. [http://www.chemistry.org/portal/a/c/s/1/acsdisplay.html?DOC=patentwatch%5Carchive%5C011204_patentwatch.html source] | ||
| + | |||
| + | === Pathway associated with anti-androgen === | ||
| + | |||
| + | * Dihydrotestosterone | ||
| + | ** Formed by peripheral conversion of testosterone by 5-alpha reductase | ||
| + | ** Binds to androgen receptor on susceptible hair follicles | ||
| + | * Hormone-receptor complex activates genes responsible for gradual transformation of large terminal follicles to miniaturized (progressive diminution of hair shaft diameter and length in response to systemic androgens) follicles | ||
| + | |||
| + | [[Image:5-alpha-reductase inhibition.jpeg|center|500 px]] | ||
| + | |||
| + | ==== Structure-Activity Relationships(SARs) ==== | ||
| + | [[Image:SAR_map.gif|center|720px]] | ||
| + | |||
| + | === Pathway associated with Minoxidil (vasodilators) === | ||
| + | Minoxidil is a well know drug used for the treatment of alopecia. A co-relation between Sesquiterpene lactone (Helenalin) produced from Arnica montana and Minoxidil is illustrated in the figure below. Arnica montana, a Vasodilator, acts on the NO/cGMP Pathway through T-cells, B-cells and epithelial cells & abrogates kappa B-driven gene expression. | ||
| + | [[image:vasodiator-rev.jpg|800 px|center]] | ||
| + | |||
| + | == Alopecia IPMap == | ||
| + | [http://www.dolcera.com/client/d8r3/hairloss_map.htm Dolcera IPMap for Alopecia] | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | |||
| + | == Patent activity in China == | ||
| + | ===Treatment approaches=== | ||
| + | {|border="2" cellspacing="0" cellpadding="4" width="100%" | ||
| + | |align = "center"|'''Treatment approach''' | ||
| + | |align = "center"|'''Patent number''' | ||
| + | |align = "center"|'''Priority year''' | ||
| + | |align = "center"|'''Assignee/Inventor''' | ||
| + | |- | ||
| + | |rowspan = "7"|Vasodilators | ||
| + | |[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN200510107497.8&leixin=fmzl&title=治疗瘀血阻滞型脱发的中草药汤剂及制备方法&ipc=A61K36/804(2006.01)I CN1772105] | ||
| + | |2005 | ||
| + | |叶明伟 | ||
| + | |- | ||
| + | |[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=CN1772139&F=0 CN1772139] | ||
| + | |2005 | ||
| + | |王亚杰 | ||
| + | |- | ||
| + | |[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN03139861.8&leixin=fmzl&title=一种可用于治疗脱发、白发的天然中草药提取组合物及应用&ipc=A61K35/78 CN1569080] | ||
| + | |2003 | ||
| + | |谈汝标 | ||
| + | |- | ||
| + | |[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN02155404.8&leixin=fmzl&title=毛囊激活液&ipc=A61K35/78 CN1506103] | ||
| + | |2002 | ||
| + | |赵章光 | ||
| + | |- | ||
| + | |[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN01127395.X&leixin=fmzl&title=一种止脱生发药物及其制备方法&ipc=A61K35/78 CN1403100] | ||
| + | |2001 | ||
| + | |范希田 | ||
| + | |- | ||
| + | |[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN96116925.7&leixin=fmzl&title=免洗养发生发香波&ipc=C11D3/48 CN1165181] | ||
| + | |1996 | ||
| + | |殷国健 | ||
| + | |- | ||
| + | |[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN88103853.9&leixin=fmzl&title=一种通络生发香波&ipc=A61K7/06 CN1031022] | ||
| + | |1988 | ||
| + | |天津市轻工业化学研究所 | ||
| + | |- | ||
| + | |Hair matrix activator | ||
| + | |[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN02111941.4&leixin=fmzl&title=一种含中西药复方的育发剂&ipc=A61K7/06 CN1463693] | ||
| + | |2002 | ||
| + | |朱静建 | ||
| + | |- | ||
| + | |Anti-androgen <nowiki>+</nowiki> Vasodilator | ||
| + | |[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN96109964.X&leixin=fmzl&title=一种治疗脂溢性脱发的高效低副作用外用药物&ipc=A61K35/78 CN1150043] | ||
| + | |1996 | ||
| + | |梅晓春 | ||
| + | |- | ||
| + | |} | ||
| + | |||
| + | === Details of treatment approaches=== | ||
| + | |||
| + | {|border="2" cellspacing="0" cellpadding="4" width="100%" align="left" | ||
| + | |align = "center"|'''Patent number''' | ||
| + | |align = "center"|'''Patent title''' | ||
| + | |align = "center"|'''Treatment approach''' | ||
| + | |align = "center"|'''Composition nature''' | ||
| + | |align = "center"|'''Composition''' | ||
| + | |align = "center"|'''Composition action''' | ||
| + | |- | ||
| + | |align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN200510107497.8&leixin=fmzl&title=治疗瘀血阻滞型脱发的中草药汤剂及制备方法&ipc=A61K36/804(2006.01)I CN1772105]<br>YE MINGWEI (CN)<br>叶明伟 (2005) | ||
| + | |align = "justify"|Chinese herbal medicine decoction for treating blood stasis obstruction type alopecia and its prepn<br>治疗瘀血阻滞型脱发的中草药汤剂及制备方法 | ||
| + | |align = "justify"|Vasodilators | ||
| + | |align = "justify"|Herbal extract | ||
| + | |align = "justify"|Astragalus root, prepared rhizome of rehmannia, white peony root, angelica, peach kernel and sufflower | ||
| + | |align = "justify"|Promote blood circulation | ||
| + | |- | ||
| + | |align = "justify"|[http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=CN1772139&F=0 CN1772139<br>]WANG YAJIE (CN)<br>王亚杰 2005 | ||
| + | |align = "justify"|Alopecia areata treating medicine<br>一种治疗斑秃的药物 | ||
| + | |align = "justify"|Vasodilators | ||
| + | |align = "justify"|Herbal extract | ||
| + | |align = "justify"|Pinellia tuber, fleeceflower root, arborvitae seed, chickení s gizzard membrane, prepared rhizome of rehmannia, Poris cocos, Codonopsis pilosula, etc | ||
| + | |align = "justify"|Promote blood circulation | ||
| + | |- | ||
| + | |align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN03139861.8&leixin=fmzl&title=一种可用于治疗脱发、白发的天然中草药提取组合物及应用&ipc=A61K35/78 CN1569080]<br>TAN RUBIAO (CN)<br>谈汝标 2003 | ||
| + | |align = "justify"|Natural Chinese herb composition for treating alopecia and leucotrichia and its application<br>一种可用于治疗脱发、白发的天然中草药提取组合物及应用 | ||
| + | |align = "justify"|Vasodilators | ||
| + | |align = "justify"|Herbal extract | ||
| + | |align = "justify"|Ginger, Cinnamomum cassia, myrrh, clove, mace nutmeg, Loranthus mulberry mistletoe, rhizoma dioscoreae, ligustrum japonicum, drynaria, fleece-flower root, and black sesame seeds | ||
| + | |align = "justify"|Enhances the hair growth and healthier hairs | ||
| + | |- | ||
| + | |align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN02111941.4&leixin=fmzl&title=一种含中西药复方的育发剂&ipc=A61K7/06 CN1463693]<br>朱静建 2002 | ||
| + | |Hair growing preparation containing compound of Chinese medicine and Western medicine<br>一种含中西药复方的育发剂 | ||
| + | |align = "justify"|Hair matrix activator | ||
| + | |Mixture of Herbal extracts and western medicine | ||
| + | |align = "justify"|Persimmon leaf, oriental arbor-vitae leaf, ginseng leaf, yellow qi, fruit of the glossy privet, polygonum multiflorum, Kudzu root, dry ginger; Plus：Minoxidil, Vitamins and derivative, cystine, serine, leucine. | ||
| + | |align = "justify"|Better and faster hair growth | ||
| + | |- | ||
| + | |align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN02155404.8&leixin=fmzl&title=毛囊激活液&ipc=A61K35/78 CN1506103]<br>赵章光2002 | ||
| + | |align = "justify"|Hair follice activating liquid<br>毛囊激活液 | ||
| + | |align = "justify"|Vasodilators | ||
| + | |align = "justify"|Herbal extract | ||
| + | |align = "justify"|Ginseng, twists the stock blue, the licorice, the Sophora flavescens and hot peppers | ||
| + | |align = "justify"|Activates the hair-follicle and enhances the hair growth. | ||
| + | |- | ||
| + | |align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN01127395.X&leixin=fmzl&title=一种止脱生发药物及其制备方法&ipc=A61K35/78 CN1403100]<br>范希田 2001 | ||
| + | |align = "justify"|Trichogen and its prepn<br>一种止脱生发药物及其制备方法 | ||
| + | |align = "justify"|Vasodilators | ||
| + | |align = "justify"|Herbal extract | ||
| + | |align = "justify"|Ginseng, ganoderma lucidum, Chinese rhubarb, polygonum multiflorum, Chinese prickly ash, ginger, grass seed | ||
| + | |align = "justify"|Promote blood circulation and enhance hair growth | ||
| + | |- | ||
| + | |align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN96116925.7&leixin=fmzl&title=免洗养发生发香波&ipc=C11D3/48 CN1165181]<br>殷国健 1996 | ||
| + | |Washing free shampoo for nourishing and growing hair<br>免洗养发生发香波 | ||
| + | |align = "justify"|Vasodilator | ||
| + | |Vitamin composition | ||
| + | |align = "justify"|Vitamin P (Bioflavonoids), Vitamin B15, Vitamin B2, nicotinic acid, bromo—geramineum | ||
| + | |align = "justify"|Stimulate hair growth | ||
| + | |- | ||
| + | |align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN96109964.X&leixin=fmzl&title=一种治疗脂溢性脱发的高效低副作用外用药物&ipc=A61K35/78 CN1150043]<br>梅晓春 1996 | ||
| + | |Efficient low-side effect external use medicine for curing seborrheic baldness<br>一种治疗脂溢性脱发的高效低副作用外用药物 | ||
| + | |align = "justify"|Anti-androgen <nowiki>+</nowiki> Vasodilator | ||
| + | |Mixture of Herbal extracts and organic compounds | ||
| + | |align = "justify"|Polygonum multiflorum, Ligustrum lucidum, Morus alba, Rehmannia glutinosa, Eclipta prostrata, Saliva miltiorrhiza, Carthamus tinctorius, Cnidium monnieri, Sophora flavescens, Dictamnus dasycarpus, Kochia scoparia, and antioxidants | ||
| + | |align = "justify"|Inhibit the excess secretion of the sebaceous glands, increase the blood circulation on scalp and enhance the hair growth | ||
| + | |- | ||
| + | |align = "justify"|[http://search.sipo.gov.cn/sipo/zljs/hyjs-yx-new.jsp?recid=CN88103853.9&leixin=fmzl&title=一种通络生发香波&ipc=A61K7/06 CN1031022]<br>天津市轻工业化学研究所 1988 | ||
| + | |Channel-stimulating and hair-growing hair shampoo<br>一种通络生发香波 | ||
| + | |align = "justify"|Vasodilators | ||
| + | |Herbal extract <nowiki>+</nowiki> detergent | ||
| + | |align = "justify"|<font color="#454545">Herbal extracts, Penetration media, Detergents.</font> | ||
| + | |align = "justify"|Increases the blood circulation under the scalp, reduces the hair los | ||
| + | |- | ||
| + | |}<br clear="all"> | ||
| + | |||
| + | |||
| + | ==<span style="color:#C41E3A">Like this report?</span>== | ||
| + | <p align="center"> '''This is only a sample report with brief analysis''' <br> | ||
| + | '''Dolcera can provide a comprehensive report customized to your needs'''</p> | ||
| + | {|border="2" cellspacing="0" cellpadding="4" align="center" " | ||
| + | |style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized Alopecia report from Dolcera</span>]''' | ||
| + | |- | ||
| + | | align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services] | ||
| + | |align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services] | ||
| + | |align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard] | ||
| + | |- | ||
| + | |align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services] | ||
| + | |align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes] | ||
| + | |align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus] | ||
| + | |- | ||
| + | |align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services] | ||
| + | |align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services] | ||
| + | |align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools] | ||
| + | |- | ||
| + | |} | ||
| + | <br> | ||
== Conclusions == | == Conclusions == | ||
| Line 1,022: | Line 1,016: | ||
* The top companies are Merck, L’Oreal and Smithkline. | * The top companies are Merck, L’Oreal and Smithkline. | ||
| − | == | + | ==Contact Dolcera== |
| − | + | ||
| − | + | ||
| − | == | + | {| style="border:1px solid #AAA; background:#E9E9E9" align="center" |
| + | |- | ||
| + | ! style="background:lightgrey" | Contact Dolcera | ||
| + | |- | ||
| + | | '''Email''': [mailto:info@dolcera.com info@dolcera.com] | ||
| + | |- | ||
| + | | '''Phone''': +1-650-269-7952 | ||
| + | |} | ||
Latest revision as of 04:04, 4 December 2014
Rationale
- "Medication for men plagued by hair loss has become a topic of interest in Japan since a drug company began marketing it at the end of last year." March 5th, 2006 – Source
- "An increasing number of companies are apparently turning the Chinese fear of a bald spot into big bucks with some doing so well they are branching out into other countries." February 16, 2006 – Source
- "There is something in the air, or should we say in the hair, these days. Scientific research into hair loss remedies has never been more active or more exciting." June 7, 2006 - Source
Introduction
Hair basics
- Hair is a complex and delicate part of the body.
- Keeping it healthy and beautiful is a challenge.
- Hair grows everywhere on the body with the exception of lips, eyelids, palms of the hands and soles of the feet.
- Hair is basically a form of skin.
- Hair is made up of a protein called keratin.
- Each shaft of hair is made of two or three inter-twined layers of keratin which grow from a follicle beneath the skin.
- Hair Structure - Source
- Hair Cycle - Source
What causes hair loss?
- Decrease in growth of hair
- Increase in shedding of hair
- Breakage of hair
- Conversion of thick terminal hairs to thin vellus hairs
Both men and women lose hair for similar reasons. Hair loss in men is often more dramatic, and follows a specific pattern of loss, one of which has been termed “Male Pattern Baldness" or "Androgenetic Alopecia".
Types of alopecia
- Alopecia Areata (AA): Hair loss occurring in patches anywhere on the body.
- Alopecia Totalis (AT): Total loss of the hair on the scalp.
- Alopecia Universalis (AU): Total loss of all hair on the body.
- Alopecia Barbae: Loss of facial hair (for a man) especially in the beard area.
- Alopecia Mucinosa: A type of alopecia which results in scaley patches.
- Androgenetic Alopecia (AGA): Also known as male pattern baldness. It is a thinning of the hair to an almost transparent state, in both men or women. It is thought to be a hereditary form of hair loss.
- Traction Alopecia: Traction alopecia is usually due to excessive pulling or tension on hair shafts as a result of certain hair styles. It is seen more often in women, particularly those of East Indian and Afro-Caribbean origin. Hair loss depends on the way the hair is being pulled. Prolonged traction alopecia can stop new hair follicles from developing and leads to permanent hair loss.
- Anagen Effluvium: This hair loss is generally caused by chemicals such as those used to treat cancer. Initially it causes patchy hair loss, which often then leads to total hair loss. The good news is that when you stop using these chemicals the hair normally grows back (usually about 6 months later). Other drugs also can cause hair loss. Many medicines used to treat even common diseases can cause hair loss.
- Scarring Alopecia: A form of alopecia which leaves scarring on the area of hair loss.
- Telogen Effluvium: A form of hair loss where more than normal numbers of hair fall out. There is a general 'thinning' of the hair. Unlike some other hair and scalp conditions, it is temporary and the hair growth usually recovers. (Source)
Androgenetic alopecia
- Gradual onset
- Transition from large, thick, pigmented terminal hairs to thinner, shorter, indeterminate hairs and finally to short, wispy, non-pigmented vellus hairs in the involved areas
- Characterized by a receding hairline and/or hair loss on the top of the head
Main causes
- Genetic predisposition
- Hormonal effect of androgen
- Reduction of blood circulation around hair follicle
- Deactivation of hair matrix cells
Some facts from Japan
- Market size: ¥ 30 Billion
- Number of products: more than 100
(JICST-EPlus - Japanese Science & Technology)
IP activity over the years
The graph indicates:
- Number of patents filed every 5 years (except for first 7 years).
- First solution proposed in 1973
- Filing trend indicates steep rise in activity recently.
Major players
- Active assignees
Assignees currently active with more than 5 patents to their credit during 2000-2005.
- Warner with 9 patents,
- Bristol with 6 and
- Abbott with 5.
Taxonomy
Interactive Taxonomy
Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy
Click on the red arrow on the side of a node name to view the content for that particular node in the dashboard
Treatment Approaches
Composition of treatment for causes are identified and categorized as follows:
- Anti-androgens (Finasteride) source
- Vasodilators (Minoxidil) source
- Double action (Anti-androgen + Vasodilator)
- Hair matrix cells activator
| Cause | Treatment approach | Pathways affected |
|---|---|---|
| Hormonal effect of androgen | Anti-androgens | Testosterone pathway |
| Reduction of blood circulation around hair follicle | Vasodilators (eg. Minoxidil) | NO/cGMP Pathway |
| Deactivation of hair matrix cells | Hair matrix cells activator |
|
Anti-androgens
- Anti-androgens are used in hormone therapy.
- Anti-androgens are designed to affect the hormones made in the adrenal glands. They don't stop the hormones from being made, but they stop them from having an effect leading to hair loss.
What causes hair loss?
- Testosterone is reduced to its active metabolite, Dihydrotestosterone (DHT) by the enzyme 5 alpha reductase.
- DHT attaches to androgen receptor sites at the hair follicle.
- DHT causes gradual miniaturization of the follicle, which eventually results in hair loss.
How do anti-androgens treat hair loss?
- Anti-androgens compete with DHT to bind to the androgen receptor.
- Upon binding of anti-androgen in place of DHT, follicle miniaturization is lowered and hair loss prevented.
Functions of Anti-androgen
IP Map for anti-androgen
| Pat/Pub# | Nature | Composition | Composition action |
|---|---|---|---|
| US20060009430
BLOTECH (2004) |
Natural extracts | Palmetto berry extract (fatty acids & sterols), Pumpkin seed extract (Vitamins-B, alpha-linolenic acid, amino acids and phytosterols), Quercetin (Flavonoids) and Beta-sitosterol (Rice bran, wheat germ, corn oils and soybeans) | Fatty acids – Inhibit testosterone
Sterols - Mechanism of action unknown. Quercetin results in cell growth cycle. Beta-sitosterol reduce inflammation on scalp |
| US20060009427
WARNER LAMBERT(2004) |
Organic compound | New class of 4-cycloalkoxy benzonitrile derivatives and salts | Acts as androgen receptor modulator and blocks formation of DHT. |
| US20050085467
WARNER LAMBERT(2004) |
Organic compound | New class of 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives. | The compounds inhibit, or decrease, activation of androgen receptor by androgens. |
| US20050118282
APHIOS Corp (2003) |
Natural extracts | Supercritical fluid isolate of Saw Palmetto and Sperol (Serenoa repens berry) and their analogs or derivatives. | Modulates androgenic activity by inhibiting 5.alpha.-reductase activity. |
| US20060009429
Fundacion Pablo Cassara (2003) |
Nucleotide | Pharmacologically active oligonucleotides (encompass both DNA and S-DNA bond) | Oligonucleotides inhibit androgen receptor (AR) expression at very low concentrations in skin and hair follicle |
| US20030007941
PFIZER INC (2001) |
Organic compound | Thyromimetic compounds (structurally similar to thyronine) with finasteride, or cyproterone acetate | Activates thyroid hormone receptors in hair follicle which in turn promote elasticisation of follicle walls and hair follicle |
| US20030073616
N/A (1995) |
Peptides/nucleic acid | Bradykinin antagonist (peptide of plasma origin from kininogen precursor-kallikrein) | Inhibits synthesis of bradykinin receptors or compounds by binding to B2 receptor |
| EP0279010
KAO Corp (1987) |
Natural extracts | Walnut extract (leaves/pericarps) with an organic solvent | Blocks formation of DHT |
Minoxidil (Vasodilators)
- Minoxidil is a "potassium channel opener" that leads to vasodilation.
- The drug is available in two forms. Oral minoxidil is used to treat high blood pressure and the topical solution form is used to treat hair loss and baldness.
What causes hair loss?
- A thick network of tiny veins and arteries line the outer wall of the follicle. Blood pumps through the bulb and hair via this network.
- DHT accumulates in the hair follicles and roots, constricting the blood supply of oxygen and nutrients to the hair roots; which is also seen to possibly contribute towards hair loss.
How does Minoxidil treat hair loss?
- Minoxidil is applied to the scalp topically, where it dilates blood vessels in the scalp and sustains the hair follicles for longer period of time.
- Minoxidil is thought to have a direct mitogenic effect on epidermal cells, as has been observed both in vitro and in vivo. Though the mechanism of its action for causing cell proliferation is not very clear, minoxidil is thought to prevent intracellular calcium entry. Calcium normally enhances epidermal growth factors to inhibit hair growth, and Minoxidil by getting converted to minoxidil sulfate acts as a potassium channel agonist and enhances potassium ion permeability to prevent calcium ions from entering into cells. (Source)
- Minoxidil sulfate (MS) appears to be the active metabolite responsible for hair growth stimulation.
Functions of Vasodilators
IP Map for Vasodilators
| Pat/Pub# | Nature | Composition | Composition action |
|---|---|---|---|
| US20040157856
WARNER LAMBERT(2002) |
Organic compound | Benzopyran compounds | Rapidly metabolizes, and causes reduced cardiovascular effects as compared to other known potassium channel openers |
| US20050053572
LG HOUSEHOLD & HEALTH CARE(2001) |
Natural extracts | Sophora flavescens extract (alkaloids & flavonoids, luteolin-7-glucose and cytosine) Hinokitiol (Taiwan hinoki oil, Aomori, Western Red Cedar oil) and Nicotinamide (Vitamin B complex) | Promotes function of cell activity and dilates blood vessels |
Double action (Anti-androgen + Vasodilator)
- Combination of Vasodilator + Anti-androgen (double action) composition for effective treatment of Male-Pattern Baldness.
What is the problem with using only Anti-androgen therapy?
- Anti-androgen is not effective in addressing the issue of vasocontriction around hair follicles due to sebum oil build up.
- Anti-androgen only prevents binding of DHT to androgen receptors. However, the effects of improper oxygen and nutrient supply to the brain due to vasocontriction still remains and gradually causes hair loss.
What is the problem with using only Vasodilator (or Minoxidil only) therapy?
- Vasodilator or Minoxidil-based products are generally not effective in stopping hair loss as vasodilators (or Minoxidil) do not block the harmful effects of DHT in the scalp and hair follicles.
- Vasodilators or Minoxidil simply dilate blood vessels in the scalp. However, the harmful DHT still gets produced in the body, enters the scalp and hair follicles causing hair loss.
How is the combination of Anti-androgens and Vasodilator (or Minoxidil) effective?
- Anti-androgens target the problem of DHT binding to androgen receptors and prevents follicle miniaturization.
- Vasodilators like Minoxidil cause vasodilation and therefore improve supply of oxygen and nutrients to the hair follicle and roots.
- Combination therapy therefore proves to be much more effective than individual therapy.
Functions of (Anti-androgen + Vasodilators)
IP Map for (Anti-androgen + Vasodilators)
| Pat/Pub# | Nature | Composition | Composition action |
|---|---|---|---|
| US20060052405
N/A(2000) |
Peptides | Testosterone blocker or vascular toner (Flutamide, cyproterone acetate, spironolactone, progesterone, or analogs or derivatives) and minoxidil mixed along with non-retinoid penetration enhancer and sunscreen | Inhibits 5.alpha.-reductase activity (block DHT) and increase blood flow on the scalp |
| US20050123577
L'OREAL(2000) |
Peptides | Prostaglandin (polyunsaturated fatty acids) EP-2, EP-3 EP-4 receptor agonist with Minoxidil, 2,4-diaminopyrimidine 3-oxide, and Aminexil, cyclic AMP | Minoxidil (designed to mimic nitric oxide's effects) grows hair via prostaglandin-H synthase stimulation. EP-3 and EP-4 are expressed in anagen hair follicles which induce a reduction in the level of cAMP |
| US6447762
COLOMER GROUP(1999) |
Natural extract | Hop extract (oil contains terpenes and humulene), Rosemary extract (hydroalcohol), Swertia extract (glycol with a swertiamarin), Silanodiol salicylate (biologically active silicon compound) | Inhibits activity of 5-alpha-reductase, protects follicular cell membranes by neutralizing action of oxidation reaction in tissues, stimulates hair follicles and blood circulation to the hair root, supplies oxygen and nutrients to base of follicle, retains humidity, avoids dehydration of scalp |
Hair matrix cell activator
Hair matrix cell activator is a substance that acts at the matrix cells in the hair follicle preventing their degradation.
What causes hair loss?
- Stem cells are interspersed within the basal layer of the outer root sheath and in an area called the bulge.
- Stem cells migrate to hair matrix where they start to divide and differentiate, under the influence of substances produced by cells of the dermal papilla.
- Perifollicular matrix cells undergo slow degradation which prevents follicle stimulation.
- Hair follicle activation is required for hair growth and thus inhibition of follicle activation eventually leads to hair loss.
How does hair cell matrix activator treat hair loss?
- Hair cell matrix activator slows down and inhibits degradation of the perifollicular matrix.
- This leads to an increase in hair follicle matrix cells that differentiate from progenitor stem cells.
- Matrix activator allows activation of hair matrix cells and therefore follicle stimulation leading to hair growth.
Functions of Hair matrix cell activator
IP Map for Hair matrix cell activator
| Pat/Pub# | Nature | Composition | Composition action |
|---|---|---|---|
| US20020052498
SHISEIDO(1999) |
Organic compound | (2-substituted oxyphenyl) alkanamide derivative and its salt | Mechanism of action has not been made clear, having excellent hair follicle activating action and regrowth promoting effect |
| US20040071647
L'OREAL(1998) |
Peptides | Metalloprotease (MMP-9) inhibitor (thiol or a hydroxamate) other than chelating calcium ions | Reducing the expression of MMPs (Metalloproteases) in the scalp - slows down or inhibits the degradation of the perifollicular matrix (extracellular matrix surrounding the hair follicle) |
Technology mapping based on patents analyzed
IPMap: Composition nature matrix
| Year | Organic Compound | Natural extracts | Peptides | Nucleotides | Natural extract + Organic comp |
|---|---|---|---|---|---|
| 2005 | .... | .... | .... | .... | UNILEVER (1) |
| 2004 | WARNER (1) | BLOTECH (1) | .... | .... | KAO (1) |
| 2003 | WARNER (1) | APHIOS (1) | .... | FUNDACION (1) | .... |
| 2002 | WARNER (1) | .... | .... | .... | .... |
| 2001 | PFIZER (1) | LG HEALTH-CARE (1) | .... | .... | .... |
| 2000 | .... | .... | L’OREAL (1) / N/A (1) | .... | .... |
| 1999 | SHISEDIO (1) | COLOMER (1) | .... | .... | .... |
| 1998 | .... | .... | L’OREAL (1) | .... | .... |
| 1995 | .... | .... | N/A (1) | .... | .... |
| 1987 | .... | KAO (1) | .... | .... | .... |
| 1982 | UNILEVER (1) | .... | .... | .... | .... |
Focus of patents
| Focus of patents | Patent no. | Rec. no. |
|---|---|---|
| 2-substituted oxyphenyl alkanamide derivative having excellent hair growth effect. | US20020052498 | 1 |
| Thyromimetic compounds, and its role in treating hair loss | US20030007941 | 2 |
| Saw Palmetto berry extract, pumpkin seed extract, sitosterol and quercetin for the treatment and prevention of the biologically detrimental effects of DHT | US20060009430 | 3 |
| 4-cycloalkoxy benzonitriles and its use as androgen receptor modulators | US20060009427 | 4 |
| Supercritical fluid isolate of Saw Palmetto, Sperol for inhibition of 5-.alpha.-reductase activity | US20050118282 | 5 |
| New class of quinolin-2-ones and chromen-2-ones andtheir use as androgen receptor antagonists | US20050085467 | 6 |
| Antiandrogen oligonucleotides usable for the treatment of dermatological androgen-related disorders | US20060009429 | 7 |
| Bradykinin antagonists for stimulating or inducing hair growth and/or arresting hair loss | US20030073616 | 8 |
| Extract from walnut leaves and/or pericarps as 5 alpha -reductase inhibitor | EP0279010 | 9 |
| Stimulating hair growth using benzopyrans | US20040157856 | 10 |
| Sophora flavescens extract, Coicis semen extract, clove extract, etc for promoting hair growth, function of cell activity and dilating peripheral blood vessels. | US20050053572 | 11 |
| Compositions to prevent or reduce hair loss | US20060052405 | 12 |
| Prostaglandin EP-3 receptor antagonists for reducing hair loss | US20050123577 | 13 |
| Synergic effect arising from the interaction of active ingredients, consisting of three plant extracts and a synthetic organosilicic compound for prevent hair loss and stimulate hair growth | US6447762 | 14 |
| Metalloprotease inhibitors to induce and/or stimulate the growth | US20040071647 | 15 |
| Method of decreasing sebum production and pore size | US20050277699 | 16 |
| Method for reducing sebum on the hair and skin | US4529587 | 17 |
Technology focus
Distribution of patents
By patent types
By key ingredients
By target disease
Key ingredients vs. Target disease
Target species
Mode of administration
Product type vs. Product form
Patents by target diseases
| Target disease/ disorder | Patent no. | Rec. no. |
|---|---|---|
| Alopecia areata, alopecia pityrodes or alopecia seborrheica, or androgenic alopecia (i.e. male pattern baldness) | US20020052498 | 1 |
| Alopecia areata, male pattern baldness and female pattern baldness | US20030007941 | 2 |
| Androgenic alopecia (i.e. male pattern baldness), prostatic hyperplasia or both. | US20060009430 | 3 |
| Inappropriate activation of the androgen receptor, acne, oily skin, alopecia | US20060009427 | 4 |
| Prostatic hyperplasia, prostatic cancer, hirsutism, acne, male pattern baldness, seborrhea, and other diseases related to androgen hyperactivity | US20050118282 | 5 |
| Alopecia, acne, oily skin, prostrate cancer, hirsutism, and benign prostate hyperplasia | US20050085467 | 6 |
| Androgen-associated hair loss and androgen-skin related disorders. | US20060009429 | 7 |
| Androgenetic or androgenic alopecia or androgeno-genetic alopecia | US20030073616 | 8 |
| Diseases caused by testosterone (male-pattern alopecia) | EP0279010 | 9 |
| Alopecia areata, female pattern hair loss, hair loss secondary to chemotherapy or radiation treatment, stress-related hair loss, self-induced hair loss, scarring alopecia, and alopecia in non-human mammal | US20040157856 | 10 |
| Male pattern alopecia | US20050053572 | 11 |
| Alopecia, androgenic alopecia | US20060052405 | 12 |
| Hair loss | US20050123577 | 13 |
| Male pattern alopecia | US6447762 | 14 |
| Androgenetic, androgenic or androgenogenetic alopecia | US20040071647 | 15 |
| Curing other scalp related problems | US20050244362 | 16 |
List of patents
Pathways and linkages
Pathways associated with hair matrix cell activation
Molecular mediators of hair follicle embryogenesis: Identification of the molecular pathways controlling differentiation and proliferation in mammalian hair follicles provides the crucial link to understanding the regulation of normal hair growth, the basis of hereditary hair loss diseases, and the origin of follicle-based tumors. Homeobox (hox), hedgehog (hh), patched (ptc), wingless (wg}/wnt, disheveled (dsh), engrailed (en), Notch 1 and armadillo/B-catenin genes are all critical for hair follicle.
- Wnt pathway: Maintains hair-inducing activity of the dermal papilla.
- Hedgehog pathway: Sonic hedgehog (SHH) signaling plays a critical role in hair follicle development. Sonic hedgehog gene. Sonic hedgehog, SHH for short, helps guide hair follicles from a resting stage into growth activity. SHH is particularly important in the embryonic formation of hair follicles.
- STAT pathway
- TGF beta/BMP Pathway: Bone morphogenetic protein (BMP) signaling have been implicated in the regulation of both proliferation and differentiation in the hair follicle. BMP2 is expressed in the embryonic ectoderm, but then localizes to the early hair follicle placode and underlying mesenchyme. BMP4 is expressed in the early dermal condensate. Research results show that BMPs are a key component of the signaling network controlling hair development and are required to induce the genetic program regulating hair shaft differentiation in the anagen hair follicle. Transforming growth factor beta (TGF-beta), inhibits mitogen - induced dermal papilla cell proliferation
- FGF Pathway: Fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) potentiate the growth of dermal papilla cells. It is proposed that these proteins increase the synthesis of stromelysin (an enzyme, matrix metalloproteinase) which acts on the papilla cells and accelerates their growth.
- MAPK Pathway: Mitogen-activated protein kinase (MAPK) activation, increases keratinocyte turnover.
- NOTCH Pathway: Notch-1 is expressed in ectodermal-derived cells of the follicle, in the inner cells of the embryonic placode and the follicle bulb, and in the suprabasal cells of the mature outer root sheath. Delta-1, one of the three ligands is only expressed during embryonic follicle development and is exclusive to the mesenchymal cells of the pre-papilla located beneath the follicle placode, and appears to promote and accelerate placode formation, while suppressing placode formation in surrounding cells. Other ligands, Serrate 1 and Serrate 2, are expressed in matrix cells destined to form the inner root sheath and hair shaft.
Pathways associated with Anti Androgen
Players of WNT inhibition Pathway
| Patent no. | Key compound | Players of inhibition |
|---|---|---|
| US6664247 | Pyrazole compounds | GSK3 |
| US6989385 | Pyrazole compounds | GSK3 |
| WO2005012256 | Pyrazole compounds | CDK,GSK3 |
| US6974819 | Pyrimidine derivative | GSK3 |
| US6743791 | Heterocyclic compounds | AKT3, GSK-3, ERK2 |
| US20050277773 | Pyrrolo[3,2-d]pyrimidine derivatives | GSK3 |
| US20040072836 | Aza-oxindole derivatives | GSK3, AKT, PKC |
| EP1477489 | Pyrrolopyrimidine derivatives | GSK3 |
| WO0056710 | 3-(Anilinomethylene) oxindoles | GSK3, AKT, PKC |
| WO2003011287 | Pyrazolon derivatives | GSK3, ß-catenin |
| US6924141 | Lithium chloride, Wnt3/4/ 7 | ß-catenin, GSK3, Wnt |
| US6706685 | Peptide sequence | ß-catenin |
| US6683048 | Peptide sequence | a-catenin, ß-catenin |
| US6677116 | Peptide sequence LXXLL | ß-catenin |
| US6303576 | Peptide sequence LXXLL | ß-catenin |
Role of Pyrazole compounds in Wnt Pathway
Pyrazole
- Pyrazole (C3H4N2) refers both to the class of simple aromatic ring organic compounds of the heterocyclic series characterized by a 5-membered ring structure composed of three carbon atoms and two nitrogen atoms in adjacent positions and to the unsubstituted parent compound. Being so composed and having pharmacological effects on humans, they are classified as alkaloids although they are not known to occur in nature.
- Pyrazoles are produced synthetically through the reaction of a,ß-unsaturated aldehydes with hydrazine and subsequent dehydrogenation
- Pyrazoles are used for their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, tranquilizing, muscle relaxing, psychoanaleptic, anticonvulsant, monoamineoxidase inhibiting, antidiabetic and antibacterial activities.
- Structurally related compounds are pyrazoline and pyrazolidine.
GSK3 inhibition by pyrazole compounds
| US6989385
|
US6664247
|
WO2005012256
|
|---|---|---|
| R1=T-Ring D, wherein
T is a valence bond and Ring D = 5-6 membered aryl or heteroaryl ring; R2 = hydrogen or C1-4 aliphatic and R2'= hydrogen; R3 = -R, -OR, or -N(R4)2, wherein R = hydrogen, C1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, and L is -O-, -S-, or -NH-; and Ring D is substituted by up to three substituents selected from -halo, -CN, -NO2, -N(R4)2, optionally substituted C1-6 aliphatic group, -OR, -C(O)R, -CO2R, -CONH(R<4>), -N(R4)COR, -N(R4)CO2R, -SO2N(R4)2, -N(R4)SO2R, -N(R6)COCH2N(R4)2, -N(R6)COCH2CH2N(R4)2, or -N(R6)COCH2CH2CH2N(R4)2, wherein R = hydrogen, C1-6 aliphatic, phenyl, 5-6 membered heteroaryl ring, or 5-6 membered heterocyclic ring |
X = R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, S02, C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length;
R1 is hydrogen; carbocyclic or heterocyclic group having from 3 to 12 ring members; or C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from 0, S, NH, SO, S02; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy). |
X is a groupR1-A-NR4-or a 5-or 6-membered carbocyclic or heterocyclic ring;
A is a bond,SO2, C=O, NRg (C=O) or O(C=O) wherein Rg is hydrogen orC14 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy;Y is a bond or an alkylene chain of 1,2 or 3 carbon atoms in length;R'is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e. g. fluorine), hydroxy, C1-4 hydrocarbyloxy, amino, mono-ordi-Cl 4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected fromO, S, NH, SO, SO2 ;R2 is hydrogen; halogen;C14 alkoxy (e. g. methoxy); or aC14 hydrocarbyl group optionally substituted by halogen (e. g. fluorine), hydroxyl orC14 alkoxy (e. g. methoxy);R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; andR4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e. g. fluorine), hydroxyl or C1-4 alkoxy (e. g. methoxy). |
Inhibition by amine derivatives
Patent Number: US6989385 Applicant: Vertex Pharmaceuticals Incorporated Title: Pyrazole compounds useful as protein kinase inhibitors
Basic Structure:
Derivatives of pyrimidine-pyrazole amine disclosed in US6989385 patent
Patent Number: US7008948 Applicant: Vertex Pharmaceuticals Incorporated Title: Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors
Basic Structure
Derivatives of pyrimidine-pyrazole amine disclosed in US7008948 patent
Patent Number: US6977262 Assignee: Mitsubishi Pharma Corporation Title: Dihydropyrazolopyridine compounds and pharmaceutical use thereof
Basic Structure:
Derivatives of pyrimidine-pyrazole amine disclosed in US6977262 patent
Patent Number: US6664247 Assignee: Vertex Pharmaceuticals Incorporated Title: Pyrazole compounds useful as protein kinase inhibitors
Basic Structure:
Derivatives of pyrimidine-pyrazole amine disclosed in US6664247 patent
Patent Number: US2004224944 Assignee: VERTEX PHARMACEUTICALS INC Title: Pyrazole compounds useful as protein kinase inhibitors
Basic Structure:
Derivatives of pyrimidine-pyrazole amine disclosed in US2004224944 patent
GSK-3 Inhibition Mechanism - Phosphorylation
- GSK-3 inhibition targets treatment of chemotherapy-induced alopecia source
- In the canonical Wnt signaling cascade, adenomatous polyposis coli (APC), axin, and GSK3 constitute the so-called destruction complex, which controls the stability of beta-catenin. It is generally believed that four conserved Ser/Thr residues in the N terminus of beta-catenin are the pivotal targets for the constitutively active serine kinase GSK3. GSK3 covalently modifies beta-catenin by attaching phosphate groups (from ATP) to serine, and threonine residues. In so doing, the functional properties of the protein kinase’s substrate (beta-catenin) are modified.
- In the absence of Wnt signals, glycogen synthase kinase (GSK) is presumed to phosphorylate the N-terminal end of beta-catenin, thus promote degradation of beta-catenin and subsequent ubiquitination and proteasomal targeting.
- Exposure of cells to Wnts leads to inactivation of GSK-3 through an as yet unclear mechanism.The phosphoprotein Dishevelled is required, after receptor-ligand interaction, to transduce the signal that results in the inactivation of GSK-3. As a result, beta-catenin is dephosphorylated and escapes the ubiqduitylation-dependent destruction machinery.
- Unphosphorylated beta-catanin accumulates in the cytoplasm and translocates to the nucleus, where it can associate with the TCF/LEFs and become a transcriptional transactivator.
Key points
- Beta-catenin phosphorylation at serine 45 (Ser45), threonine 41 (Thr41), Ser37, and Ser33 is critical for beta-catenin degradation. source
- Regulation of beta-catenin phosphorylation is a central part of the canonical Wnt signaling pathway. source
- Ser-X-X-X-Ser (X is any amino acid) motif is obligatory for beta-catenin phosphorylation by GSK3.source
- Beta-catenin phosphorylation/degradation and its regulation by Wnt can occur normally in the absence of Thr41 as long as the Ser-X-X-X-Ser motif/spacing is preserved. [httSp://pubs.acs.org/cgi-bin/abstract.cgi/bichaw/2006/45/i16/abs/bi0601149.html source]
GK3 Inhibition:
- GSK3 is regulated by phosphorylation.
- Phosphorylation of GSK3beta on Ser9 (Ser21 in GSK3alpha) by protein kinase B (PKB) causes its inactivation is the primary mechanism responsible for growth factor inhibition of this kinase. Activation of GSK3beta is dependent upon the phosphorylation of Tyr216 (Tyr279 in GSK3alpha). Upon activation, it has been shown to phosphorylate a number of different cellular proteins, including p53, c-Myc, c-Jun, heat shock factor-1 (HSF-1), beta-catenin and cyclin D1. source
- GSK3 is inhibited by phosphorylation of serine-9 or serine-21 in GSK3beta and GSK3alpha, respectively. source
- GSK3’s substrate specificity is unique in that phosphorylation of substrate only occurs if a phosphoserine or phosphotyrosine is present four residues C-terminal to the site of GSK phosphorylation. source
- A phosphorylation cascade starts from GSK3 itself and initiates it in beta-catenin. source
- Thus our goal is to stop the phosphorylation of the serine and threonine residue of GSK3.
- The figure below illustrates the phosphorylation mechanism of serine and threonine by ATP.
- We can't stop conversion of ADP to ATP that relaseas Phosphorous group causing Phosphorylation.
- We can only block the oxygen atom on serine and threonine as a result which will in turn stop Phosphorylation.
- The two probable ways of blocking the oxygen atom are (a) As oxygen is a Lewis acid with strong electron donating capacity, so usually a strong electron pair acceptor can easily bind to oxygen atom and preventing phosphorylation or (b) breaking of the -OH bond with the carbon atom.
Serine - pyrazole reaction
- The T-loop of GSK-3 is tyrosine phosphorylated at Y216 and Y279 in GSK-3b and GSK-3a, respectively, but not threonine phosphorylated. Y216/Y279 phosphorylation could play a role in forcing open the substrate (e.g, beta-catanin)-binding site.
- Thus, T-loop tyrosine might facilitate substrate phosphorylation but is not strictly required for kinase activity.
- Stimulation of cells with pyrazole compounds cause inactivation of GSK-3 through phosphorylation (S9 of GSK-3 beta and S21 of GSK-3 alpha), which inhibits GSK-3 activity. Thus leading to dephosphorylation of substrates (e.g., beta-catanin) resulting in their functional activation and consequent increased hair follicle morphogenisis.
- Phosphorylation of S9/S21 creates a primed pesudosubstrate that binds intramolecularly to the positively charged pocket of the GSK-3. This folding precludes phosphorylation of substrates (eg., beta-catanin) because the catalytic groove is occupied. The mechanism of inhibition is competitive.
- A consequence of this is that primed substrates, in high enough concentrations, out-compete the pesudosubstrate and thus become phosphorylated.
- Thus, small molecule inhibitors modeled to fit in the positively charged pocket of the GSK-3 kinease domain could potentially be very effective for selective inhibition of primed substrates.
Proposed mechanisms to regulate GSK-3 source
- inactivation of GSK-3 through serine phosphorylation
- activation of GSK-3 through tyrosine phosphorylation
- inactivation of GSK-3 through tyrosine dephosphorylation
- Covalant modifications of substrates through priming phosphorylation
- inhibition or facilation of GSK-3 mediated substrate phosphorylation thriugh interation of GSK-3 with binding or scaffolding proteins
- targeting of GSK-3 to different subcellular localizations
- differential usage of isoforms or splice variants to alter subcellular localization or substrate specificity
- integration of parellel signals conveyed by a signal stimulus.
Key Finding
- Pyrazole compounds with inhibition constant (Ki) of <0.1 mM are a good starting point for developing molecules that can inhibit serine/threonine protein kinase (such as GSK-3) and the proteins they help to regulate. source
Pathway associated with anti-androgen
- Dihydrotestosterone
- Formed by peripheral conversion of testosterone by 5-alpha reductase
- Binds to androgen receptor on susceptible hair follicles
- Hormone-receptor complex activates genes responsible for gradual transformation of large terminal follicles to miniaturized (progressive diminution of hair shaft diameter and length in response to systemic androgens) follicles
Structure-Activity Relationships(SARs)
Pathway associated with Minoxidil (vasodilators)
Minoxidil is a well know drug used for the treatment of alopecia. A co-relation between Sesquiterpene lactone (Helenalin) produced from Arnica montana and Minoxidil is illustrated in the figure below. Arnica montana, a Vasodilator, acts on the NO/cGMP Pathway through T-cells, B-cells and epithelial cells & abrogates kappa B-driven gene expression.
Alopecia IPMap
Patent activity in China
Treatment approaches
| Treatment approach | Patent number | Priority year | Assignee/Inventor |
| Vasodilators | CN1772105 | 2005 | 叶明伟 |
| CN1772139 | 2005 | 王亚杰 | |
| CN1569080 | 2003 | 谈汝标 | |
| CN1506103 | 2002 | 赵章光 | |
| CN1403100 | 2001 | 范希田 | |
| CN1165181 | 1996 | 殷国健 | |
| CN1031022 | 1988 | 天津市轻工业化学研究所 | |
| Hair matrix activator | CN1463693 | 2002 | 朱静建 |
| Anti-androgen + Vasodilator | CN1150043 | 1996 | 梅晓春 |
Details of treatment approaches
| Patent number | Patent title | Treatment approach | Composition nature | Composition | Composition action |
| CN1772105 YE MINGWEI (CN) 叶明伟 (2005) |
Chinese herbal medicine decoction for treating blood stasis obstruction type alopecia and its prepn 治疗瘀血阻滞型脱发的中草药汤剂及制备方法 |
Vasodilators | Herbal extract | Astragalus root, prepared rhizome of rehmannia, white peony root, angelica, peach kernel and sufflower | Promote blood circulation |
| CN1772139 WANG YAJIE (CN) 王亚杰 2005 |
Alopecia areata treating medicine 一种治疗斑秃的药物 |
Vasodilators | Herbal extract | Pinellia tuber, fleeceflower root, arborvitae seed, chickení s gizzard membrane, prepared rhizome of rehmannia, Poris cocos, Codonopsis pilosula, etc | Promote blood circulation |
| CN1569080 TAN RUBIAO (CN) 谈汝标 2003 |
Natural Chinese herb composition for treating alopecia and leucotrichia and its application 一种可用于治疗脱发、白发的天然中草药提取组合物及应用 |
Vasodilators | Herbal extract | Ginger, Cinnamomum cassia, myrrh, clove, mace nutmeg, Loranthus mulberry mistletoe, rhizoma dioscoreae, ligustrum japonicum, drynaria, fleece-flower root, and black sesame seeds | Enhances the hair growth and healthier hairs |
| CN1463693 朱静建 2002 |
Hair growing preparation containing compound of Chinese medicine and Western medicine 一种含中西药复方的育发剂 |
Hair matrix activator | Mixture of Herbal extracts and western medicine | Persimmon leaf, oriental arbor-vitae leaf, ginseng leaf, yellow qi, fruit of the glossy privet, polygonum multiflorum, Kudzu root, dry ginger; Plus：Minoxidil, Vitamins and derivative, cystine, serine, leucine. | Better and faster hair growth |
| CN1506103 赵章光2002 |
Hair follice activating liquid 毛囊激活液 |
Vasodilators | Herbal extract | Ginseng, twists the stock blue, the licorice, the Sophora flavescens and hot peppers | Activates the hair-follicle and enhances the hair growth. |
| CN1403100 范希田 2001 |
Trichogen and its prepn 一种止脱生发药物及其制备方法 |
Vasodilators | Herbal extract | Ginseng, ganoderma lucidum, Chinese rhubarb, polygonum multiflorum, Chinese prickly ash, ginger, grass seed | Promote blood circulation and enhance hair growth |
| CN1165181 殷国健 1996 |
Washing free shampoo for nourishing and growing hair 免洗养发生发香波 |
Vasodilator | Vitamin composition | Vitamin P (Bioflavonoids), Vitamin B15, Vitamin B2, nicotinic acid, bromo—geramineum | Stimulate hair growth |
| CN1150043 梅晓春 1996 |
Efficient low-side effect external use medicine for curing seborrheic baldness 一种治疗脂溢性脱发的高效低副作用外用药物 |
Anti-androgen + Vasodilator | Mixture of Herbal extracts and organic compounds | Polygonum multiflorum, Ligustrum lucidum, Morus alba, Rehmannia glutinosa, Eclipta prostrata, Saliva miltiorrhiza, Carthamus tinctorius, Cnidium monnieri, Sophora flavescens, Dictamnus dasycarpus, Kochia scoparia, and antioxidants | Inhibit the excess secretion of the sebaceous glands, increase the blood circulation on scalp and enhance the hair growth |
| CN1031022 天津市轻工业化学研究所 1988 |
Channel-stimulating and hair-growing hair shampoo 一种通络生发香波 |
Vasodilators | Herbal extract + detergent | Herbal extracts, Penetration media, Detergents. | Increases the blood circulation under the scalp, reduces the hair los |
Like this report?
This is only a sample report with brief analysis
Dolcera can provide a comprehensive report customized to your needs
Conclusions
- Hair loss medication is a very active area of research and intellectual property development.
- One of the most promising areas of development is the area of Anti-androgens.
- The top companies are Merck, L’Oreal and Smithkline.
Contact Dolcera
| Contact Dolcera |
|---|
| Email: info@dolcera.com |
| Phone: +1-650-269-7952 |
